Zobrazeno 1 - 10
of 64
pro vyhledávání: '"X. Lataste"'
Autor:
X. Lataste
The recognition of the dopaminergic properties of some ergot derivatives has initiated new therapeutical approaches in endocrinology as well as in neurology. The pharmacological characterization of the different ergot derivatives during the last deca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b577e8ff886b42623dbdf27a80317a00
http://doc.rero.ch/record/291215/files/S0317167100046266.pdf
http://doc.rero.ch/record/291215/files/S0317167100046266.pdf
Publikováno v:
Movement Disorders. 7:239-243
A selective dopamine D1-receptor agonist, CY 208-243, was administered to 23 de novo patients who had had Parkinson disease (PD) for less than or equal to 3 months. The drug was first used as monotherapy and then in some patients in combination with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::711891afbd6c9c5c56eb105c48844810
https://doi.org/10.1002/mds.870070309
https://doi.org/10.1002/mds.870070309
Autor:
M Hoyer, Olivier Rascol, X Lataste, C Lücking, D Hirt, Werner Poewe, Urpo K. Rinne, H Teräväinen, E Dupont, N Fabre
Publikováno v:
Clinical Neuropharmacology. 13:303-311
The antiparkinsonian efficacy and tolerability of CQA 206-291, a novel ergoline derivative with potent dopamine agonist properties, were studied during 2 months of treatment in 72 parkinsonian patients. In 36 de novo patients (patients who have not p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb1b238776709e103aef0f98df5d1787
https://doi.org/10.1097/00002826-199008000-00004
https://doi.org/10.1097/00002826-199008000-00004
Autor:
A. Azcona, X. Lataste
Publikováno v:
Drugs. 40:52-57
Calcium-related mechanisms are an integral part of metabolic reactions during acute cerebral infarction. In an animal model of stroke, the calcium antagonist isradipine was shown to protect neurons against ischaemia. In order to improve the neurologi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7ec1c3160c7fdddb8d790a353aaa16d
https://doi.org/10.2165/00003495-199000402-00013
https://doi.org/10.2165/00003495-199000402-00013
Autor:
A. Floesser, I. Bruenig-Traebert, Daniela Eser, M. Merz, Rainer Rupprecht, K. Kucher, R. Zaninelli, C. Schuele, A. Krebs-Brown, X. Lataste
Publikováno v:
European Neuropsychopharmacology. 16:S248-S249
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b487dd19a30be54dc0bfe9292aac09a2
https://doi.org/10.1016/s0924-977x(06)70215-2
https://doi.org/10.1016/s0924-977x(06)70215-2
Publikováno v:
Neurology. 44(11 Suppl 9)
The therapeutic profile of a new antispastic drug cannot be defined solely on the basis of placebo-controlled studies. Its potential advantages must be evaluated in comparison with existing drugs. This review compares the efficacy and tolerability of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::22516912a79f51b418bbadbf7f200a1d
https://pubmed.ncbi.nlm.nih.gov/7970011
https://pubmed.ncbi.nlm.nih.gov/7970011
Publikováno v:
Psychopharmacology. 112(1)
The selective 5HT3 antagonist tropisetron was studied in 91 outpatients meeting DSM-III criteria for Generalized Anxiety Disorder. Following a placebo washout period of up to 1 week, one of three active treatments (tropisetron 0.5 mg, 5 mg, or 25 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb39047476b75ea7fc045f6a2096ac41
https://pubmed.ncbi.nlm.nih.gov/7871001
https://pubmed.ncbi.nlm.nih.gov/7871001
Autor:
X. Lataste
Publikováno v:
International journal of sports medicine. 13
The concept of blood-brain barrier has moved over the past years from a passive and relatively immutable structure to a more dynamic interface between blood and brain tissue. The transport mechanisms regulating this adaptative interface might be cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c66808fe34c5a4a3326019183e47209
https://pubmed.ncbi.nlm.nih.gov/1483788
https://pubmed.ncbi.nlm.nih.gov/1483788
Autor:
André Rascol, Geneviève Durrieu, Jean-Michel Senard, O. Rascol, Jean-Louis Montastruc, M. A. Tran, X. Lataste
Publikováno v:
Neurology. 40:707-707
We found blood pressure (BP), heart rate (HR), plasma norepinephrine (NE), and epinephrine (E) levels in the lying and the standing positions to be similar in never-treated parkinsonian patients (stages 1 and 2) and age-matched controls. CY 208-243,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62683c73494be87e37644993a2821e00
https://doi.org/10.1212/wnl.40.4.707
https://doi.org/10.1212/wnl.40.4.707
Autor:
R. Markstein, A. M. Bonnet, Yves Agid, X. Lataste, C. D. Marsden, Temlett Ja, Niall Quinn, Peter Jenner, E. Pourcher
Publikováno v:
Movement Disorders. 4:261-265
The effect of stimulation of cerebral dopamine D-1 receptors by CY 208-243 on motor disability was tested in MPTP-treated parkinsonian marmosets and patients with Parkinson's disease. CY 208-243 (0.5-1.25 mg/kg s.c.) produced a dose-related reversal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca48b01959c2fffd876232157d8d747
https://doi.org/10.1002/mds.870040307
https://doi.org/10.1002/mds.870040307